Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Mild Hepatic Impairment Compared to Participants With Normal Hepatic Function
NCT05283915
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
10
Enrollment
INDUSTRY
Sponsor class
Conditions
Hepatic Function Abnormal
Interventions
DRUG:
tolebrutinib
Sponsor
Sanofi